CurrentmhnPolicy CP.PMN.288

Nirmatrelvir and Ritonavir (Paxlovid)

Defines medical necessity and prior authorization criteria for use of co-packaged nirmatrelvir and ritonavir (Paxlovid) for treatment of mild-to-moderate COVID-19 in adults at high risk of progression; applies to members under the payer's Commercial, HIM, and Medicaid lines.

Policy Summary

Payermhn

PolicyNirmatrelvir and Ritonavir (Paxlovid)

Policy CodePolicy CP.PMN.288

Change TypeNo material changes

Effective DateSep 1, 2023

Next Review DateN/A

Key ActionSubmit prior authorization with documentation that the member meets all approval criteria (diagnosis, age ≥18, symptom onset ≤5 days, ≥1 risk factor, and dosing within limits).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 daysApproval duration

≥18Minimum age

≤5 daysInitiation window

600/200 mgMax daily dose

Commercial,HIM,MedicaidLines of business

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy (COVID-19)

Covered when ALL of the following are met:

Initial COVID-19 treatment criteria: 1. Diagnosis of COVID-19; 2. Age ≥ 18 years; 3. Onset of COVID-19 symptom(s) within 5 days; 4. Member has ≥ 1 risk factor for progression to severe COVID-19 (see Appendix D); 5. A second course of Paxlovid is not prescribed for treatment of continued symptoms after an initial course (e.g., rebound symptoms, long-COVID, post-acute sequelae of SARS-CoV-2); 6. Dose does not exceed 600 mg nirmatrelvir (4 tablets) with 200 mg ritonavir (2 tablets) per day for 5 days.symptom onset ≤ 5 days; age ≥ 18; max dose 600 mg nirmatrelvir + 200 mg ritonavir per day

Approval duration: 5 days

Other Indications / Off-label Requests

For other indications:

Alternate/Off-label pathway: 1. If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy (for example, newly approved indication, age expansion, or new dosing regimen), follow the applicable formulary/no-coverage or non-formulary policy for the member's line of business (see policy references: CP.CPA.190, HIM.PA.33, CP.PMN.255; or CP.CPA.190, HIM.PA.103, CP.PMN.16). OR 2. If the requested use (diagnosis, age, dosing) is NOT listed under section III (Diagnoses/Indications for which coverage is NOT authorized) and criterion 1 does not apply, refer the request to the off-label use policy for the relevant line of business (CP.CPA.09, HIM.PA.154, CP.PMN.53).

See related policies for specific procedures

Coverage does not include use of co-packaged nirmatrelvir and ritonavir (Paxlovid) for pre-exposure prophylaxis or post-exposure prophylaxis for prevention of COVID-19. Non–FDA approved indications that are not specifically addressed in this policy are not covered unless the provider supplies sufficient documentation of efficacy and safety consistent with the applicable off‑label use policy (see related off‑label policies for commercial, marketplace, and Medicaid lines).

Requests for indications outside the FDA‑approved COVID‑19 treatment indication will be evaluated per the referenced off‑label use policies and evidence of coverage documents; absent adequate supporting documentation, such requests are subject to denial.

Coverage determinations and administration of benefits under this clinical policy are governed by the terms, conditions, exclusions, and limitations of the member’s coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract). Applicable state and federal requirements and Health Plan‑level administrative policies also apply. Where state Medicaid provisions conflict with this policy, the state Medicaid coverage provisions take precedence.

Re‑authorization or extension beyond the initial approved course of Paxlovid is not permitted. Longer treatment courses and a second course for rebound symptoms or long‑COVID are not authorized due to insufficient data on efficacy, and members must meet initial approval criteria for any additional requests.

CDC and Appendix guidance note that COVID‑19 rebound can occur 2–8 days after initial recovery and that reinfection timing varies; current evidence does not support repeated or extended Paxlovid courses for these scenarios, and ongoing studies are evaluating safety and efficacy of retreatment.

Prior Authorization and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for an initial course of Paxlovid. Providers must request authorization and ensure documentation demonstrates the member meets all approval criteria (see Initial Approval Criteria). Requests lacking sufficient clinical documentation will be denied.

Initial course only — approval duration: 5 days
Dose limit: ≤ 600 mg nirmatrelvir + 200 mg ritonavir per day for 5 days

Prior Authorization

Prior Authorization and Supply Sourcing

Prior authorization requests should include the source of medication supply when applicable. The policy no longer requires exhaustion of U.S. government–provided supplies prior to coverage; information on patient assistance programs is available in the Appendix for eligible patients.

Do not require prior government-supply exhaustion
See Appendix for patient assistance program information

Denial Risk

Re-authorization Restriction

Re-authorization or extension of an initial Paxlovid treatment course is not permitted. A second course is not approved for continued or recurrent symptoms following an initial course (including rebound or long-COVID).

Re-authorization/extension not allowed
Second course not for rebound or post-acute sequelae

Documentation Required

Required Documentation

Provider must submit clinical documentation (e.g., office chart notes, lab results, other clinical information) that supports the member meets all approval criteria. Requests without supporting documentation will be denied.

Include office notes, test results, symptom onset date, risk factors for progression

Note

Coverage Decisions and Administration

Coverage decisions and administration of benefits are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable contract. Providers are expected to use professional medical judgment; this policy is a guide to medical necessity and not a guarantee of payment.

Coverage subject to plan contract, EOC, state/federal requirements
Providers remain responsible for clinical care and judgment

Step Therapy

No Step Therapy Requirement

There are no specific step therapy requirements for Paxlovid under this policy.

Background and Drug Information

Paxlovid is a co‑packaged oral regimen combining nirmatrelvir, a SARS‑CoV‑2 main protease (Mpro) inhibitor, with ritonavir, an HIV‑1 protease inhibitor used here to inhibit CYP3A and boost nirmatrelvir exposure. The combination is FDA‑approved for the treatment of mild‑to‑moderate COVID‑19 in adults who are at high risk for progression to severe disease, including hospitalization or death.

Ritonavir’s potent CYP3A inhibition introduces significant drug‑drug interaction risks and may create contraindications with commonly prescribed medications; these interactions should be assessed prior to prescribing. Paxlovid is not approved for pre‑ or post‑exposure prophylaxis.

Available clinical guidance and the policy appendices note that recurrent or rebound symptoms after an initial course have been observed (typically 2–8 days after recovery) and that longer or repeat courses of Paxlovid are not currently authorized because evidence is insufficient to support retreatment.

Definitions and Plan Scope

inv-16: Paxlovid — co-packaged nirmatrelvir and ritonavir definition

Drug compositionCo-packaged nirmatrelvir (SARS-CoV-2 main protease inhibitor) and ritonavir (HIV-1 protease inhibitor and CYP3A inhibitor)

Brand namePaxlovid (co-packaged nirmatrelvir and ritonavir)

Mechanism noteRitonavir acts as a pharmacokinetic enhancer via CYP3A inhibition, increasing nirmatrelvir exposure

inv-17: FDA approved indication — treatment of mild-to-moderate COVID-19 in adults at high risk for progression

Approved indicationTreatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death

LimitationsNot approved for pre-exposure or post-exposure prophylaxis for prevention of COVID-19

PopulationAdults (age ≥ 18 years) at high risk for progression

inv-18: Health Plan — definition of health plan adopting this policy

DefinitionA Health Plan is a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates

Scope of policy useThis clinical policy provides a guide to medical necessity to assist in coverage decisions and benefit administration; it is not a contract or guarantee of payment

Provider expectationsProviders are expected to exercise professional medical judgment; the policy does not dictate clinical care

OpenPayer

Nirmatrelvir and Ritonavir (Paxlovid)

Coverage and Medical Necessity Criteria

Dosing and Coding Notes

Prior Authorization and Provider Requirements

Background and Drug Information

Definitions and Plan Scope